<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Wang Z</submitter><funding>National High Technology Research and Development Program of China</funding><funding>Kaifeng Municipal Science and Technology Research and Development Project</funding><funding>Beijing Physician Scientist Training Project</funding><funding>Henan Provincial Science and Technology Research and Development Project</funding><funding>the Natural Science Foundation of Beijing, China</funding><pagination>e70971</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12759265</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>30(1)</volume><pubmed_abstract>Aortic dissection is a life-threatening cardiovascular emergency with limited pharmacological options. This study focuses on elucidating the multi-target and multi-pathway mechanisms through which morusin mitigates aortic dissection progression, integrating network pharmacology, single-cell transcriptomics and experimental validation. Multi-database analysis identified 281 morusin targets and 1741 ad-related genes, with 84 overlaps. Enrichment analyses highlighted IL-17, HIF-1 and MAPK signalling pathways as potential regulatory hubs. Protein-protein interaction network analysis identified seven key targets, all showing high binding affinity to morusin in molecular docking. Single-cell transcriptomics revealed cell-type-specific dysregulation, notably MAPK8 upregulation in fibroblasts and immune cells. In vitro, morusin dose-dependently inhibited AngII-induced vascular smooth muscle cell proliferation and modulated IL-17 pathway gene expression. In vivo, morusin attenuated aortic dilation and reduced morbidity and mortality in a BAPN-induced AD mouse model. These findings suggest that morusin mitigates AD progression by targeting key inflammatory and apoptotic pathways, supporting its potential as a multi-target therapeutic candidate.</pubmed_abstract><journal>Journal of cellular and molecular medicine</journal><pubmed_title>Integrated Network Pharmacology, Single-Cell Transcriptomics Unveil the Mechanistic Role of Morusin in Aortic Dissection.</pubmed_title><pmcid>PMC12759265</pmcid><funding_grant_id>BJPSTP-2024-21</funding_grant_id><funding_grant_id>NO. 2023YFA1800904</funding_grant_id><funding_grant_id>NO.L232031</funding_grant_id><funding_grant_id>NO.252102311099</funding_grant_id><funding_grant_id>NO.2020YFA0803700</funding_grant_id><funding_grant_id>NO.2203023</funding_grant_id><funding_grant_id>NO.J230039</funding_grant_id><pubmed_authors>Niu C</pubmed_authors><pubmed_authors>Zhang H</pubmed_authors><pubmed_authors>Xie Z</pubmed_authors><pubmed_authors>Zheng L</pubmed_authors><pubmed_authors>Xiang Y</pubmed_authors><pubmed_authors>Fu Y</pubmed_authors><pubmed_authors>Jiang C</pubmed_authors><pubmed_authors>Wang Z</pubmed_authors><pubmed_authors>Jiao H</pubmed_authors><pubmed_authors>Lin N</pubmed_authors></additional><is_claimable>false</is_claimable><name>Integrated Network Pharmacology, Single-Cell Transcriptomics Unveil the Mechanistic Role of Morusin in Aortic Dissection.</name><description>Aortic dissection is a life-threatening cardiovascular emergency with limited pharmacological options. This study focuses on elucidating the multi-target and multi-pathway mechanisms through which morusin mitigates aortic dissection progression, integrating network pharmacology, single-cell transcriptomics and experimental validation. Multi-database analysis identified 281 morusin targets and 1741 ad-related genes, with 84 overlaps. Enrichment analyses highlighted IL-17, HIF-1 and MAPK signalling pathways as potential regulatory hubs. Protein-protein interaction network analysis identified seven key targets, all showing high binding affinity to morusin in molecular docking. Single-cell transcriptomics revealed cell-type-specific dysregulation, notably MAPK8 upregulation in fibroblasts and immune cells. In vitro, morusin dose-dependently inhibited AngII-induced vascular smooth muscle cell proliferation and modulated IL-17 pathway gene expression. In vivo, morusin attenuated aortic dilation and reduced morbidity and mortality in a BAPN-induced AD mouse model. These findings suggest that morusin mitigates AD progression by targeting key inflammatory and apoptotic pathways, supporting its potential as a multi-target therapeutic candidate.</description><dates><release>2026-01-01T00:00:00Z</release><publication>2026 Jan</publication><modification>2026-05-28T03:23:45.053Z</modification><creation>2026-05-28T03:12:45.217Z</creation></dates><accession>S-EPMC12759265</accession><cross_references><pubmed>41482800</pubmed><doi>10.1111/jcmm.70971</doi></cross_references></HashMap>